

Eamonn M M Quigley

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9169088/eamonn-m-m-quigley-publications-by-year.pdf>
Version: 2024-04-02

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

212 papers	12,144 citations	52 h-index	109 g-index
233 ext. papers	14,835 ext. citations	6.1 avg, IF	7.08 L-index

#	Paper	IF	Citations
212	Bacterial overgrowth 2022 , 1155-1167		
211	Small Intestinal Bacterial Overgrowth, Pathophysiology and its implications for Definition and Management.. <i>Gastroenterology</i> , 2022 ,	13.3	4
210	Lost microbes of COVID-19: , depletion and decreased microbiome diversity associated with SARS-CoV-2 infection severity.. <i>BMJ Open Gastroenterology</i> , 2022 , 9,	3.9	3
209	The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021 , 18, 649-667	24.2	165
208	Prevalence of cardiovascular risk factors in a nationally representative adult population with inflammatory bowel disease without atherosclerotic cardiovascular disease. <i>American Journal of Preventive Cardiology</i> , 2021 , 6, 100171	1.9	0
207	The alternative serotonin transporter promoter P2 impacts gene function in females with irritable bowel syndrome. <i>Journal of Cellular and Molecular Medicine</i> , 2021 , 25, 8047-8061	5.6	1
206	Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. <i>Gastroenterology</i> , 2021 , 160, 99-114.e3	13.3	285
205	Chronic constipation in adults: Contemporary perspectives and clinical challenges. 2: Conservative, behavioural, medical and surgical treatment. <i>Neurogastroenterology and Motility</i> , 2021 , 33, e14070	4	2
204	The Dilemma of Persistent Irritable Bowel Syndrome Symptoms in Patients with Quiescent Inflammatory Bowel Disease. <i>Gastroenterology Clinics of North America</i> , 2021 , 50, 689-711	4.4	1
203	Reply to: Postbiotics - when simplification fails to clarify. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021 , 18, 827-828	24.2	7
202	Effects of the vibrating capsule on colonic circadian rhythm and bowel symptoms in chronic idiopathic constipation. <i>Neurogastroenterology and Motility</i> , 2020 , 32, e13890	4	10
201	Commentary: faecal microbiota transplantation-from home brew to holy grail. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 208-209	6.1	
200	Peppermint Oil in Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2020 , 159, 395-396	13.3	5
199	Efficacy of psychological therapies for irritable bowel syndrome: systematic review and network meta-analysis. <i>Gut</i> , 2020 , 69, 1441-1451	19.2	53
198	Recent advances in modulating the microbiome. <i>F1000Research</i> , 2020 , 9,	3.6	23
197	Nutraceuticals as modulators of gut microbiota: Role in therapy. <i>British Journal of Pharmacology</i> , 2020 , 177, 1351-1362	8.6	13
196	Efficacy of soluble fibre, antispasmodic drugs, and gut-brain neuromodulators in irritable bowel syndrome: a systematic review and network meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2020 , 5, 117-131	18.8	58

195	AGA Clinical Practice Update on Small Intestinal Bacterial Overgrowth: Expert Review. <i>Gastroenterology</i> , 2020 , 159, 1526-1532	13.3	33
194	The probiotic in the management of Coronavirus: A theoretical basis. <i>International Journal of Immunopathology and Pharmacology</i> , 2020 , 34, 2058738420961304	3	19
193	Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis. <i>Gut</i> , 2020 , 69, 74-82	19.2	68
192	Antibiotics and probiotics in inflammatory bowel disease: when to use them?. <i>Frontline Gastroenterology</i> , 2020 , 11, 62-69	2.6	16
191	Gut microbiota abnormalities, small intestinal bacterial overgrowth, and non-alcoholic fatty liver disease: An emerging paradigm. <i>Indian Journal of Gastroenterology</i> , 2020 , 39, 9-21	1.9	18
190	Irritable bowel syndrome in celiac disease - relationships to celiac disease antibodies and levels of pro-inflammatory cytokines. <i>Revista De Gastroenterologia Del Peru: Organo Oficial De La Sociedad De Gastroenterologia Del Peru</i> , 2020 , 40, 127-135	0.3	
189	Systematic review with meta-analysis: cholecystectomy for biliary dyskinesia-what can the gallbladder ejection fraction tell us?. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 49, 654-663	6.1	8
188	Symptoms and the small intestinal microbiome - the unknown explored. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019 , 16, 457-458	24.2	4
187	Letter: meta-analysis of prebiotics, probiotics, synbiotics and antibiotics in IBS. Authors Reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 49, 1254-1255	6.1	1
186	Microbiome Modulation in Liver Disease. <i>Clinical Liver Disease</i> , 2019 , 14, 149-151	2.2	
185	Effect of Antidepressants and Psychological Therapies in Irritable Bowel Syndrome: An Updated Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2019 , 114, 21-39	0.7	185
184	Prebiotics and Probiotics in Digestive Health. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 333-344	6.9	115
183	The Spectrum of Small Intestinal Bacterial Overgrowth (SIBO). <i>Current Gastroenterology Reports</i> , 2019 , 21, 3	5	53
182	Therapeutic implications of the gastrointestinal microbiome. <i>Current Opinion in Pharmacology</i> , 2018 , 38, 90-96	5.1	9
181	The role of the microbiome and the use of probiotics in gastrointestinal disorders in adults in the Asia-Pacific region - background and recommendations of a regional consensus meeting. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018 , 33, 57-69	4	16
180	Definition, Pathogenesis, and Management of That[Cursed]Dyspepsia. <i>Clinical Gastroenterology and Hepatology</i> , 2018 , 16, 467-479	6.9	25
179	Better Understanding and Recognition of the Disconnects, Experiences, and Needs of Patients with Irritable Bowel Syndrome with Constipation (BURDEN IBS-C) Study: Results of an Online Questionnaire. <i>Advances in Therapy</i> , 2018 , 35, 967-980	4.1	14
178	A Systematic Review and Meta-Analysis Evaluating the Efficacy of a Gluten-Free Diet and a Low FODMAPs Diet in Treating Symptoms of Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2018 , 113, 1290-1300	0.7	173

177	Pharmabiotic Manipulation of the Microbiota in Gastrointestinal Disorders: A Clinical Perspective. <i>Journal of Neurogastroenterology and Motility</i> , 2018 , 24, 355-366	4.4	11
176	The Gut-Brain Axis and the Microbiome: Clues to Pathophysiology and Opportunities for Novel Management Strategies in Irritable Bowel Syndrome (IBS). <i>Journal of Clinical Medicine</i> , 2018 , 7,	5.1	44
175	A Critical Review of the Current Clinical Landscape of Gastroparesis. <i>Gastroenterology and Hepatology</i> , 2018 , 14, 140-145	0.7	4
174	Highlights of the Updated Evidence-Based IBS Treatment Monograph. <i>Gastroenterology and Hepatology</i> , 2018 , 14, 665-667	0.7	
173	Autoimmune liver disease and the enteric microbiome. <i>AIMS Microbiology</i> , 2018 , 4, 334-346	4.5	1
172	Plausibility criteria for putative pathophysiological mechanisms in functional gastrointestinal disorders: a consensus of experts. <i>Gut</i> , 2018 , 67, 1425-1433	19.2	15
171	Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 48, 1044-1060	6.1	248
170	Brain Fogging and D-Lactic Acidosis: Probiotics Are Not the Cause. <i>Clinical and Translational Gastroenterology</i> , 2018 , 9, 187	4.2	9
169	Efficacy of Secretagogues in Patients With Irritable Bowel Syndrome With Constipation: Systematic Review and Network Meta-analysis. <i>Gastroenterology</i> , 2018 , 155, 1753-1763	13.3	72
168	The diagnosis of small intestinal bacterial overgrowth: Two steps forward, one step backwards?. <i>Neurogastroenterology and Motility</i> , 2018 , 30, e13494	4	12
167	American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2018 , 113, 1-18	0.7	170
166	Basic Definitions and Concepts: Organization of the Gut Microbiome. <i>Gastroenterology Clinics of North America</i> , 2017 , 46, 1-8	4.4	12
165	What can we learn from other clinical settings on the influence of the gut microbiome on the brain?. <i>Clinical Liver Disease</i> , 2017 , 9, 52-54	2.2	2
164	Gut microbiome as a clinical tool in gastrointestinal disease management: are we there yet?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2017 , 14, 315-320	24.2	71
163	Probiotics in Inflammatory Bowel Disease. <i>Gastroenterology Clinics of North America</i> , 2017 , 46, 769-782	4.4	95
162	The PAC-SYM questionnaire for chronic constipation: defining the minimal important difference. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 46, 1103-1111	6.1	27
161	Microbiota-Brain-Gut Axis and Neurodegenerative Diseases. <i>Current Neurology and Neuroscience Reports</i> , 2017 , 17, 94	6.6	290
160	Prokinetics in the Management of Functional Gastrointestinal Disorders. <i>Current Gastroenterology Reports</i> , 2017 , 19, 53	5	17

159	The Better Understanding and Recognition of the Disconnects, Experiences, and Needs of Patients with Chronic Idiopathic Constipation (BURDEN-CIC) Study: Results of an Online Questionnaire. <i>Advances in Therapy</i> , 2017 , 34, 2661-2673	4.1	26
158	Immune response in irritable bowel syndrome: A systematic review of systemic and mucosal inflammatory mediators. <i>Journal of Digestive Diseases</i> , 2016 , 17, 572-581	3.3	30
157	Irritable bowel syndrome. <i>Nature Reviews Disease Primers</i> , 2016 , 2, 16014	51.1	429
156	Overlapping irritable bowel syndrome and inflammatory bowel disease: less to this than meets the eye?. <i>Therapeutic Advances in Gastroenterology</i> , 2016 , 9, 199-212	4.7	44
155	Advancing treatment options for chronic idiopathic constipation. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 501-11	4	12
154	The Microbiome and the Liver: The Basics. <i>Seminars in Liver Disease</i> , 2016 , 36, 299-305	7.3	10
153	The Metabolic Role of the Microbiome: Implications for NAFLD and the Metabolic Syndrome. <i>Seminars in Liver Disease</i> , 2016 , 36, 312-316	7.3	16
152	Primary Biliary Cirrhosis and the Microbiome. <i>Seminars in Liver Disease</i> , 2016 , 36, 349-353	7.3	12
151	The Microbiome: What Will the Future Hold?. <i>Seminars in Liver Disease</i> , 2016 , 36, 354-359	7.3	2
150	Efficacy and Safety of Prucalopride in Chronic Constipation: An Integrated Analysis of Six Randomized, Controlled Clinical Trials. <i>Digestive Diseases and Sciences</i> , 2016 , 61, 2357-2372	4	52
149	Diet and irritable bowel syndrome. <i>Current Opinion in Gastroenterology</i> , 2015 , 31, 166-71	3	14
148	The Effect of Dietary Intervention on Irritable Bowel Syndrome: A Systematic Review. <i>Clinical and Translational Gastroenterology</i> , 2015 , 6, e107	4.2	37
147	Probiotics in Irritable Bowel Syndrome: The Science and the Evidence. <i>Journal of Clinical Gastroenterology</i> , 2015 , 49 Suppl 1, S60-4	3	20
146	THE INTESTINAL MICROBIOTA AND THE ROLE OF PROBIOTICS IN IRRITABLE BOWEL SYNDROME: a review. <i>Arquivos De Gastroenterologia</i> , 2015 , 52, 331-8	1.3	13
145	Prokinetics in the Management of Functional Gastrointestinal Disorders. <i>Journal of Neurogastroenterology and Motility</i> , 2015 , 21, 330-6	4.4	37
144	Pharmacoeconomic study of chronic constipation in a secondary care centre. <i>Irish Journal of Medical Science</i> , 2015 , 184, 863-70	1.9	3
143	Manipulation of the microbiota for treatment of IBS and IBD-challenges and controversies. <i>Gastroenterology</i> , 2014 , 146, 1554-63	13.3	121
142	The future of probiotics for disorders of the brain-gut axis. <i>Advances in Experimental Medicine and Biology</i> , 2014 , 817, 417-32	3.6	13

141	Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. <i>American Journal of Gastroenterology</i> , 2014 , 109, 1547-61; quiz 1546, 1562	0.7	447
140	The effect of fiber supplementation on irritable bowel syndrome: a systematic review and meta-analysis. <i>American Journal of Gastroenterology</i> , 2014 , 109, 1367-74	0.7	202
139	American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. <i>American Journal of Gastroenterology</i> , 2014 , 109 Suppl 1, S2-26; quiz S27	0.7	393
138	Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysis. <i>American Journal of Gastroenterology</i> , 2014 , 109, 1350-65; quiz 1366	0.7	262
137	The past 10 years of gastroenterology and hepatology-reflections and predictions. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014 , 11, 692-700	24.2	2
136	Leadership in medicine: do we need a new approach?. <i>American Journal of Gastroenterology</i> , 2014 , 109, 786-8	0.7	
135	Commentary: Probing probiotics in cirrhosis--a template for future studies?. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 39, 1334-5	6.1	2
134	Small intestinal bacterial overgrowth: what it is and what it is not. <i>Current Opinion in Gastroenterology</i> , 2014 , 30, 141-6	3	57
133	Probiotics, prebiotics & synbiotics in small intestinal bacterial overgrowth: opening up a new therapeutic horizon!. <i>Indian Journal of Medical Research</i> , 2014 , 140, 582-4	2.9	7
132	PARs for the course: roles of proteases and PAR receptors in subtly inflamed irritable bowel syndrome. <i>American Journal of Gastroenterology</i> , 2013 , 108, 1644-6	0.7	1
131	Bugs on the brain; brain in the gut--seeking explanations for common gastrointestinal symptoms. <i>Irish Journal of Medical Science</i> , 2013 , 182, 1-6	1.9	20
130	Emerging treatments for chronic constipation. <i>Expert Opinion on Emerging Drugs</i> , 2013 , 18, 365-73	3.7	8
129	Commentary: synbiotics and gut microbiota in older people--a microbial guide to healthy ageing. <i>Alimentary Pharmacology and Therapeutics</i> , 2013 , 38, 1141-2	6.1	10
128	A review of the clinical efficacy of linaclotide in irritable bowel syndrome with constipation. <i>Current Medical Research and Opinion</i> , 2013 , 29, 149-60	2.5	13
127	Fecal excretion of <i>Bifidobacterium infantis</i> 35624 and changes in fecal microbiota after eight weeks of oral supplementation with encapsulated probiotic. <i>Gut Microbes</i> , 2013 , 4, 201-11	8.8	52
126	<i>Bifidobacterium infantis</i> 35624 modulates host inflammatory processes beyond the gut. <i>Gut Microbes</i> , 2013 , 4, 325-39	8.8	229
125	CT-based estimation of intracavitary gas volumes using threshold-based segmentation: in vitro study to determine the optimal threshold range. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2012 , 56, 289-94	1.7	7
124	Epigenetics: filling in the heritability gap and identifying gene-environment interactions in ulcerative colitis. <i>Genome Medicine</i> , 2012 , 4, 72	14.4	10

123	An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. <i>Gut</i> , 2012 , 61, 997-1006	19.2	564
122	Commentary: long-term lubiprostone for constipation predominant IBS. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 35, 962-3	6.1	1
121	Prebiotics and probiotics: their role in the management of gastrointestinal disorders in adults. <i>Nutrition in Clinical Practice</i> , 2012 , 27, 195-200	3.6	52
120	Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 35, 745-67	6.1	205
119	Prucalopride: safety, efficacy and potential applications. <i>Therapeutic Advances in Gastroenterology</i> , 2012 , 5, 23-30	4.7	49
118	Portrait of an immunoregulatory Bifidobacterium. <i>Gut Microbes</i> , 2012 , 3, 261-6	8.8	80
117	Bifidobacterium infantis 35624 administration induces Foxp3 T regulatory cells in human peripheral blood: potential role for myeloid and plasmacytoid dendritic cells. <i>Gut</i> , 2012 , 61, 354-66	19.2	196
116	Carriage of Clostridium difficile in outpatients with irritable bowel syndrome. <i>Journal of Medical Microbiology</i> , 2012 , 61, 1290-1294	3.2	14
115	A global perspective on irritable bowel syndrome: a consensus statement of the World Gastroenterology Organisation Summit Task Force on irritable bowel syndrome. <i>Journal of Clinical Gastroenterology</i> , 2012 , 46, 356-66	3	106
114	Barrett's esophagus: clinical features, obesity, and imaging. <i>Annals of the New York Academy of Sciences</i> , 2011 , 1232, 36-52	6.5	4
113	Cisapride: what can we learn from the rise and fall of a prokinetic?. <i>Journal of Digestive Diseases</i> , 2011 , 12, 147-56	3.3	73
112	The enteric microbiota in the pathogenesis and management of constipation. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 2011 , 25, 119-26	2.5	65
111	Motility, heartburn and dyspepsia. <i>Alimentary Pharmacology and Therapeutics</i> , 2010 , 11, 41-50	6.1	4
110	Bacteria, genetics and irritable bowel syndrome. <i>Expert Review of Gastroenterology and Hepatology</i> , 2010 , 4, 271-6	4.2	7
109	Probiotics in gastrointestinal disorders. <i>Hospital Practice (1995)</i> , 2010 , 38, 122-9	2.2	15
108	The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. <i>Gut</i> , 2010 , 59, 325-32	19.2	472
107	Constipation, IBs and the 5-HT4 Receptor: What Role for Prucalopride?. <i>Clinical Medicine Gastroenterology</i> , 2010 , 3, CGast.S4136		8
106	Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation--a 12-week, randomized, double-blind, placebo-controlled study. <i>Alimentary Pharmacology and Therapeutics</i> , 2009 , 29, 315-28	6.1	237

105	Irritable bowel syndrome: role of food in pathogenesis and management. <i>Journal of Digestive Diseases</i> , 2009 , 10, 237-46	3.3	59
104	Prebiotics for irritable bowel syndrome. <i>Expert Review of Gastroenterology and Hepatology</i> , 2009 , 3, 487-92	4.2	6
103	Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. <i>Gut</i> , 2009 , 58, 367-78	19.2	404
102	Probiotics and Irritable Bowel Syndrome. <i>Bioscience and Microflora</i> , 2009 , 28, 119-124		1
101	An Evidence-Based Systematic Review on the Management of Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2009 , 104, S8-S35	0.7	103
100	Gastrointestinal dysfunction in neurological disease: a report of an interdisciplinary international symposium. <i>Neurogastroenterology and Motility</i> , 2008 , 6, 55-57	4	
99	Probiotics in functional gastrointestinal disorders: what are the facts?. <i>Current Opinion in Pharmacology</i> , 2008 , 8, 704-8	5.1	48
98	Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. <i>BMJ, The</i> , 2008 , 337, a2313	5.9	368
97	What is the evidence for the use of probiotics in functional disorders?. <i>Current Gastroenterology Reports</i> , 2008 , 10, 379-84	5	11
96	The QonQase. The Rome process and functional gastrointestinal disorders: the barbarians are at the gate!. <i>Neurogastroenterology and Motility</i> , 2007 , 19, 793-7	4	28
95	Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker?. <i>Gastroenterology</i> , 2006 , 130, 304-11	13.3	479
94	Irritable bowel syndrome: the burden and unmet needs in Europe. <i>Digestive and Liver Disease</i> , 2006 , 38, 717-23	3.3	69
93	Efficacy of an encapsulated probiotic <i>Bifidobacterium infantis</i> 35624 in women with irritable bowel syndrome. <i>American Journal of Gastroenterology</i> , 2006 , 101, 1581-90	0.7	605
92	Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. <i>Gastroenterology</i> , 2005 , 128, 541-51	13.3	1051
91	Irritable bowel syndrome and inflammatory bowel disease: interrelated diseases?. <i>Chinese Journal of Digestive Diseases</i> , 2005 , 6, 122-32		47
90	Review article: quality-of-life issues in gastro-oesophageal reflux disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2005 , 22 Suppl 1, 41-7	6.1	37
89	Why do we have so few effective drugs for irritable bowel syndrome? A European perspective. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2005 , 2, 436-7		5
88	Critical care dysmotility: abnormal foregut motor function in the ICU/ITU patient. <i>Gut</i> , 2005 , 54, 1351-2; discussion 1384-90	19.2	17

87	Review article: gastric emptying in functional gastrointestinal disorders. <i>Alimentary Pharmacology and Therapeutics</i> , 2004 , 20 Suppl 7, 56-60	6.1	51
86	From comic relief to real understanding; how intestinal gas causes symptoms. <i>Gut</i> , 2003 , 52, 1659-61	19.2	18
85	Intestinal motility: Normal and disturbed patterns. <i>Chinese Journal of Digestive Diseases</i> , 2003 , 4, 1-4		1
84	New developments in the pathophysiology of gastro-oesophageal reflux disease (GERD): implications for patient management. <i>Alimentary Pharmacology and Therapeutics</i> , 2003 , 17 Suppl 2, 43-51	6.1	13
83	Factors that influence therapeutic outcomes in symptomatic gastroesophageal reflux disease. <i>American Journal of Gastroenterology</i> , 2003 , 98, S24-30	0.7	25
82	Aerophagia and Intestinal Gas. <i>Current Treatment Options in Gastroenterology</i> , 2002 , 5, 259-265	2.5	6
81	Small intestinal transplantation. <i>Current Gastroenterology Reports</i> , 2001 , 3, 408-11	5	3
80	The effects of tegaserod (HTF 919) on oesophageal acid exposure in gastro-oesophageal reflux disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2000 , 14, 1503-9	6.1	70
79	Acute Intestinal Pseudo-obstruction. <i>Current Treatment Options in Gastroenterology</i> , 2000 , 3, 273-286	2.5	12
78	Is there a future for a national scientific medical journal in Ireland?. <i>Irish Journal of Medical Science</i> , 2000 , 169, 12-12	1.9	
77	Pharmacotherapy of gastroparesis. <i>Expert Opinion on Pharmacotherapy</i> , 2000 , 1, 881-7	4	13
76	Probiotics: from myth to reality. Demonstration of functionality in animal models of disease and in human clinical trials. <i>Antonie Van Leeuwenhoek</i> , 1999 , 76, 279-292	2.1	257
75	Chronic Intestinal Pseudo-obstruction. <i>Current Treatment Options in Gastroenterology</i> , 1999 , 2, 239-250	2.5	11
74	Efficacy of prolonged administration of intravenous erythromycin in an ambulatory setting as treatment of severe gastroparesis: one center's experience. <i>Journal of Clinical Gastroenterology</i> , 1999 , 28, 131-4	3	63
73	Transdermal delivery of erythromycin lactobionate--implications for the therapy of gastroparesis. <i>Alimentary Pharmacology and Therapeutics</i> , 1997 , 11, 589-92	6.1	9
72	Constipation in Parkinson's disease: objective assessment and response to psyllium. <i>Movement Disorders</i> , 1997 , 12, 946-51	7	163
71	An evaluation of an ambulatory manometry system in assessment of antroduodenal motor activity. <i>Digestive Diseases and Sciences</i> , 1996 , 41, 1531-7	4	21
70	Neuromuscular disorders in systemic malignancy and its treatment. <i>Muscle and Nerve</i> , 1996 , 19, 109-10	3.4	

69	Glucagon, stress, and portal hypertension. Plasma glucagon levels and portal hypertension in relation to anesthesia and surgical stress. <i>Digestive Diseases and Sciences</i> , 1995 , 40, 1816-23	4	7
68	Anorectal function in fluctuating (on-off) Parkinson's disease: evaluation by combined anorectal manometry and electromyography. <i>Movement Disorders</i> , 1995 , 10, 650-7	7	59
67	Anorectal manometry in the assessment of anorectal function in Parkinson's disease: a comparison with chronic idiopathic constipation. <i>Movement Disorders</i> , 1994 , 9, 655-63	7	53
66	Bile acid metabolism and biliary secretion in patients receiving orthotopic liver transplants: Differing effects of cyclosporine and FK 506. <i>Hepatology</i> , 1994 , 19, 1381-1389	11.2	21
65	The clinical pharmacology of motility disorders: the perils (and pearls) of prokinetics. <i>Gastroenterology</i> , 1994 , 106, 1112-4	13.3	14
64	Defecatory function in Parkinson's disease: response to apomorphine. <i>Annals of Neurology</i> , 1993 , 33, 490-3	9.4	99
63	Gastrointestinal symptoms in Parkinson disease: 18-month follow-up study. <i>Movement Disorders</i> , 1993 , 8, 83-6	7	105
62	Gastric compliance and motility in the portal hypertensive rat. <i>Journal of Investigative Surgery</i> , 1992 , 5, 109-14	1.2	6
61	Antroduodenal manometry. <i>Digestive Diseases and Sciences</i> , 1992 , 37, 1305-8	4	3
60	Antroduodenal manometry. <i>Digestive Diseases and Sciences</i> , 1992 , 37, 1927	4	
59	Antroduodenal manometry. Usefulness and limitations as an outpatient study. <i>Digestive Diseases and Sciences</i> , 1992 , 37, 20-8	4	97
58	Development and evaluation in an ex vivo rat model of a technique for the endoscopic assessment of mucosal defense in man. <i>Scandinavian Journal of Gastroenterology</i> , 1991 , 26, 353-60	2.4	
57	Gastrointestinal symptoms in Parkinson's disease. <i>Movement Disorders</i> , 1991 , 6, 151-6	7	294
56	Assessment of Intestinal Failure Patients115-121		
55	Intestinal Failure: Definitions and Classifications55-65		
54	Intestinal Adaptation45-54		3
53	Immunology of the Small Intestine33-44		
52	Basic Physiology of Motility, Absorption and Secretion20-32		

51	Intestinal Morphology, Intestinal Regeneration and the Promise of Tissue Engineering11-19	2
50	The History of Intestinal Failure and Transplantation1-10	
49	Intestinal Failure-Associated Liver Disease191-200	2
48	Infections in Small Bowel Transplant Recipients297-304	1
47	Intestinal Failure Related to Bariatric Surgery93-98	
46	Motility Disorders107-113	
45	Vascular Access, Including Complications142-150	2
44	Enteral Support for Children with Intestinal Failure151-159	1
43	The Use of Enteral Nutrition in the Adult with Intestinal Failure160-166	0
42	Management of Complex Fluid and Electrolyte Disturbances185-190	1
41	Psychiatric Issues in the Assessment of the Patient with Intestinal Failure201-205	
40	Munchausen Syndrome by Proxy206-211	
39	The Role of Humoral Factors in Intestinal Adaptation223-228	
38	Autologous Reconstruction of the GI Tract229-241	
37	Intestinal Transplantation: Indications and Patient Selection243-253	3
36	Isolated Small Bowel Transplantation and Combined Liver-Small Bowel Transplantation254-261	1
35	Living Donor Intestinal Transplantation262-269	
34	Isolated Liver Transplantation for Intestinal Failure-Associated Liver Disease270-274	

33	Preservation of the Intestine275-282	1
32	Immediate Postoperative Care of the Intestinal Transplant Recipient283-289	1
31	Surgical Complications of Intestinal Transplantation290-296	
30	Immunosuppression after Intestinal Transplantation305-313	
29	Immunology of Intestinal Allograft Rejection314-321	
28	Histopathology of Intestinal Transplantation322-330	
27	Long-Term Management of Intestinal Transplant Recipients331-341	
26	Management of Posttransplant Lymphoproliferative Disease342-348	
25	Results of Intestinal Transplantation349-356	
24	Psychosocial Assessment and Management of the Transplant Patient/Family in Intestinal Transplantation357-362	
23	Financial, Economic and Insurance Issues Pertaining to Intestinal Transplantation: When is too much not enough?363-377	1
22	Causes of Intestinal Failure in the Newborn66-76	
21	Congenital Enteropathies Causing Permanent Intestinal Failure77-87	
20	Inflammatory Bowel Disease and the Short Bowel Syndrome99-106	1
19	Guidelines for Home Parenteral Nutrition Support in Chronic Intestinal Failure Patients122-129	1
18	Home Parenteral Nutrition: Complications, Survival, Costs and Quality of Life130-141	5
17	Luminal Nutrient Factors in Intestinal Adaptation and their use in Therapy213-222	
16	Causes of Intestinal Failure in the Adult88-92	

15	The Enteric Flora in Intestinal Failure167-184	2
14	Food-related Symptoms of Irritable Bowel Syndrome141-158	
13	What is the Best Way to Identify and Quantify Irritable Bowel Syndrome?51-67	
12	Interface between Primary Care and Secondary Care93-117	
11	Epidemiology of Irritable Bowel Syndrome23-36	
10	Gut Hypersensitivity Related Symptoms237-262	
9	Abdominal Bloating263-276	
8	Gut Inflammation in Irritable Bowel Syndrome159-181	
7	Gut Motility Related Symptoms215-236	
6	Diagnostic and Therapeutic Horizons for Irritable Bowel Syndrome301-314	
5	Sequencing the Treatments277-299	
4	Self-Management Strategies for Irritable Bowel Syndrome119-139	
3	Psychological Factors and Treatments in Irritable Bowel Syndrome183-213	
2	Practical Approach to Clinical Assessment of Irritable Bowel Syndrome69-91	
1	Definitions and Classifications of Irritable Bowel Syndrome1-21	2